Science & Enterprise subscription

Follow us on Twitter

  • Children in the U.S. are now more likely to get infected from SARS-CoV-2 viruses, with their infection rates rising… https://t.co/OOBOF5qRow
    about 4 hours ago
  • New post on Science and Enterprise: Infographic – Covid-19 Rates Rising in U.S. Kids https://t.co/0HngWjhteI #Science #Business
    about 4 hours ago
  • Dexcom Inc., a maker of glucose monitoring systems, and University of Virginia are collaborating on extending the c… https://t.co/ZN7Zbhmh2s
    about 1 day ago
  • New post on Science and Enterprise: Dexcom, UVirginia Partner on Diabetes Technology https://t.co/4V268unvtm #Science #Business
    about 1 day ago
  • A biotechnology company is developing biologic treatments for Covid-19 infections in the gastrointestinal tract and… https://t.co/ChbVQfB86q
    about 2 days ago

Please share Science & Enterprise

DoD Funds Covid-19 G.I. Infection Therapy

Spirulina powder

A biotechnology company is developing biologic treatments for Covid-19 infections in the gastrointestinal tract and to block further disease transmission. . . . → Read More: DoD Funds Covid-19 G.I. Infection Therapy

Chip-Based RNA Biotech Raises $60M in Venture Funds

DNA chip graphic

A company developing messenger RNA therapeutics on demand from single-use biochips is raising $60 million in its second venture funding round. . . . → Read More: Chip-Based RNA Biotech Raises $60M in Venture Funds

Skeletal Stem Cells Enhanced for Bone Repair

Skull X-ray

Researchers in the U.K. created a bandage with enhanced human skeletal stem cells that in lab mice repairs simulated skull defects. . . . → Read More: Skeletal Stem Cells Enhanced for Bone Repair

Mental Health Drug Company Raises $127.5M in IPO

NASDAQ share price display

A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer. . . . → Read More: Mental Health Drug Company Raises $127.5M in IPO

Biotechs Partner on Gene-Editing Cystic Fibrosis Therapy

lung illustration

Two biotechnology companies are adding to their current collaboration to develop delivery techniques for gene-editing treatments for cystic fibrosis. . . . → Read More: Biotechs Partner on Gene-Editing Cystic Fibrosis Therapy

Early Trial Results Show Antibody Treating Covid-19

SARS-Cov-2 virus

First results from a clinical trial testing an experimental synthetic antibody, show patients receiving the therapy at a specific dosage, cleared their SARS-CoV-2 viruses within 11 days. . . . → Read More: Early Trial Results Show Antibody Treating Covid-19

Precision Cancer Therapy Start-Up Gains $110M in Early Funds

Human T-cell

A company creating cancer therapies with individualized engineered T-cells is raising $110 million in its first venture funding round. . . . → Read More: Precision Cancer Therapy Start-Up Gains $110M in Early Funds

Gilead Acquires Cancer Therapy Biotech for $21B

Investment graphic

Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B

NIH Trials Testing Covid-19 Blood Clot Therapies

Heart, circulation system

National Institutes of Health is starting two clinical trials testing a number of blood thinning treatments for people with blood clots from Covid-19 infections. . . . → Read More: NIH Trials Testing Covid-19 Blood Clot Therapies

Antibody Discovery Company Forms, Partners on Covid-19

Network pointer

A new enterprise formed to discover human therapeutic antibodies is partnering with a synthetic biology company to discover Covid-19 antibody treatments. . . . → Read More: Antibody Discovery Company Forms, Partners on Covid-19